Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer

摘要

Patients with prostate cancer generally respond to androgen withdrawal therapy, but progression to an- drogen-independence is frequently observed later. To examine whether pretreatment serum androgen status could predict disease progression in metastatic prostate cancer, pretreatment serum testosterone, histological grade, extent of bony metastasis, serum prostate-specific antigen(PSA)response to hormone therapy, and prognosis of the 40 patients with untreated metastatic prostate cancer who received endocrine therapy were evaluated.